

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number
WO 2006/013081 A1

- (51) International Patent Classification⁷: **A61K 8/73**, 8/81, A61Q 11/00
- (21) International Application Number: PCT/EP2005/008327
- (22) International Filing Date: 29 July 2005 (29.07.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0417193.0 2 August 2004 (02.08.2004) GB
0502077.1 1 February 2005 (01.02.2005) GB
- (71) Applicants (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB). **GLAXOSMITHKLINE CONSUMER HEALTH-CARE GMBH & CO KG**. [DE/DE]; Bussmatten 1, D-77815 Buehl (Baden) (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KAWA, Gertrud** [DE/DE]; GlaxoSmithKline Consumer Healthcare GmbH & Co. KG, Bussmatten 1, D-77815 Buehl (Baden) (DE). **UPPAL, Shireen** [GB/GB]; GlaxoSmithKline, St. George's Avenue, Weybridge Surrey KT13 0DE (GB). **URQUHART, David** [GB/GB]; GlaxoSmithKline, St. George's Avenue, Weybridge Surrey KT13 0DE (GB).
- (74) Agent: **THOMPSON, Clive, Beresford**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOSITION FOR XEROSTOMIA

(57) Abstract: An oral care composition is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.



WO 2006/013081 A1

NOVEL COMPOSITION FOR XEROSTOMIA

The present invention relates to mucoadhesive agent-containing compositions for oral use, such as toothpastes, sprays, mouthwashes, gels, lozenges, chewing gums, tablets, pastilles, instant powders, oral strips and buccal patches etc, and to the use of such compositions as an oral lubricant and to alleviate the discomfort associated with xerostomia.

Xerostomia, or dry mouth, is a condition in which an excessive dryness within the oral cavity occurs. Xerostomia is not itself a disease, but a symptom of various medical conditions, a side effect of radiation to the head and neck, or a side effect of a variety of medications. Xerostomia is a common complaint found often among older adults; however, does not appear to be related to age itself.

Xerostomia is often a contributing factor for both minor and serious health problems; it can affect nutrition and dental, as well as psychological health. Some common problems associated with xerostomia include a constant sore throat, burning sensations, difficulty speaking and swallowing, hoarseness and / or dry nasal passages. If left untreated, xerostomia decreases the oral pH and significantly increases the development of plaque and dental caries. Oral candidosis is one of the most common oral infections seen in association with xerostomia.

In view of the above, it would be advantageous to provide compositions for oral use as a lubricant to alleviate the discomfort associated with xerostomia.

US 5,496,558, aims to address these problems with the provision of solid-form xerostomia products in the form of a lozenge, tablet, chewing gum and pastille, comprising a lubricating polymer, polyethylene glycol, an organic acid and sorbitol. US 5,612,207 aims to address these problems with the provision of a lozenge comprising a hard candy base, a demulcent, a humectant and an organic acidulant.

However, there remains a need for alternative formulations with good mouth feel; that are able to lubricate and hydrate the mouth.

It has been found that the symptoms of dry mouth may be reduced by the use of an oral care composition comprising a combination of polyvinyl pyrrolidone (PVP) or a derivative thereof with an anionic mucoadhesive polymer.

- 5 A mucoadhesive polymer of the invention has an affinity for biological surfaces especially towards mucous membranes of the oral cavity. Mucoadhesive agents as used in the invention may be natural or synthetic.

Accordingly, the present invention provides a composition comprising PVP or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.

The compositions according to the present invention have good mouth coating, lubrication and mouth feel properties. Whilst compositions comprising an anionic mucoadhesive polymer are able to provide a good coating, they can suffer from negative sensory properties of being too tacky in use. This negative sensory property has surprisingly been overcome by the addition of PVP or a derivative thereof to an anionic mucoadhesive polymer.

Suitable derivatives of PVP include a vinyl pyrrolidone/vinyl acetate (VP/VA) copolymer or a vinyl pyrrolidone/vinyl alcohol (VP/VOH) copolymer. Preferably, compositions of the present invention comprise PVP or VP/VA copolymer

Compositions of the present invention may suitably comprise from 0.1 to 20% w/w of PVP, or a derivative thereof, preferably from, 0.5 to 10% w/w and more preferably 0.6 to 8% w/w.

The anionic mucoadhesive polymers useful in the present invention may be a cellulose gum, a saccharide gum or a polyacrylic acid polymer, or a mixture thereof.

Suitable cellulose gums include a carboxymethylcellulose (CMC) gum, for example sodium carboxymethylcellulose.

Suitable saccharide gums for use in the present invention include xanthan gum, guar gum, gum Arabic, tragacanth, gum karaya, locust bean gum and pectin or a mixture thereof. Xanthan gum is preferred.

Suitable polyacrylic acid polymers include carbomers, acrylate/C₁₀₋₃₀ alkyl acrylate cross polymers or polycarbophils available from Noveon Inc, 9911 Brecksville Road, Cleveland, Ohio 44141-3247. Preferred polyacrylic acids are carbomers or acrylate/C₁₀₋₃₀ alkyl acrylate cross polymers.

5

Suitably compositions of the present invention may comprise a combination of sodium carboxymethylcellulose and xanthan gum.

10 Suitably compositions of the present invention may comprise from 0.02 to 20% w/w of the anionic mucoadhesive polymer, preferably from 0.1 to 10% w/w, more preferably from 0.15 to 4% w/w, and most preferably from 0.2 to 2% w/w.

15 Suitably the compositions of the present invention may comprise PVP or a derivative thereof and an anionic mucoadhesive polymer in a weight ratio of from 5:1 to 1:1, preferably from 4:1 to 2:1.

20 Compositions of the present invention may further comprise a silicon based oil, such as dimethicone or simethicone in an amount up to 8%w/w, eg from 1 to 5% w/w. The hydrophobic nature of the silicon based oil enhances the lubricity of the compositions in the oral cavity.

The oral compositions of the present invention are typically formulated in the form of toothpastes, sprays, mouthwashes, gels, lozenges (including centre filled lozenges), chewing gums, tablets, pastilles, instant powders, oral strips and buccal patches etc.
25 Preferred compositions of the present invention are mouth sprays, mouthwashes and oral gels.

Known oral strips or buccal patches can be adapted to deliver the combination of polymers of the present invention to the oral cavity. For example a multilayered erodible
30 film as disclosed in WO 03/015748 and US 04/0062724 may incorporate PVP or a derivative thereof and an anionic mucoadhesive polymer of the present invention either in the adhesive first layer and/or the erodible second layer as disclosed therein. If desired a silicon based oil can be used alone or with other hydrophobic polymers to be incorporated into or to coat the erodible layer as disclosed therein.

35

Suitable orally acceptable carriers and excipients include abrasive polishing materials (especially for a dentifrice), flavouring agents, humectants, binders, sweetening agents, surfactants, preservatives, buffering agents, colouring agents and water.

- 5 Suitable humectants for use in compositions of the invention include glycerine, sorbitol, xylitol, propylene glycol or polyethylene glycol, or mixtures thereof; which humectant may be present in the range from 5 to 70%.

- 10 Suitable flavouring agents for use in the present invention include peppermint, spearmint, and fruit flavours. Flavouring agents provide an additional benefit in stimulating salivary flow, which helps alleviate the symptoms of dry mouth. If desired, additional salivary stimulants can be included such as edible organic acids, e.g. citric acid.

- 15 Suitable preservatives for use in the invention include parabens (methyl and propyl parabens), sodium benzoate, and potassium sorbate.

Suitable buffering agents for use in the invention include phosphate buffers such as disodium phosphate, sodium phosphate or citrate buffers.

- 20 Suitable surfactants for use in the invention include polyethyleneglycols (PEG), hydrogenated castor oils, sorbitan esters, polyethylene-polypropylene tri-block copolymers (such as Poloxamers™). Preferred surfactants include PEG-40 or PEG-60 hydrogenated castor oil and sorbitan esters.

- 25 Additional ingredients suitable for use in the invention include remineralising agents, antimicrobial agents, anti-caries agents, anticalculus agents, moisturising agents, breath freshening agents and desensitising agents.

- 30 Suitable antimicrobial agents for use in the invention include chlorhexidine, cetylpyridinium chloride, zinc salts or triclosan. Preferred antimicrobial agents are cetylpyridinium chloride, chlorhexidine and zinc salts.

- 35 Suitable anti-caries agents for use in the invention include a source of fluoride ions such as an alkali metal salt, for example sodium fluoride, or sodium monofluorophosphate, tin (II) fluoride or an amine fluoride salt such as Olaflur or Decaflur. Suitably the composition will comprise between 1 and 2500ppm of fluoride ions.

Compositions according to the present invention may be prepared by admixing the ingredients in the appropriate relative amounts in any order that is convenient and thereafter and if necessary including a buffering agent to adjust the pH to give the final
5 desired value.

The compositions according to the present invention will have a pH which is orally acceptable, typically ranging from about pH 5 to 10 and more preferable pH 5.5 to 8.

10 Mouthwash and mouth spray compositions may be provided in a "ready to use" form; as a concentrated solution, for dilution by the user immediately prior to use; or in solid form, such as a tablet or as instant powder in a sachet, for dissolution by the user immediately prior to use. Tablets may suitably be prepared using xylitol and/or sorbitol as the major ingredient. The sachets and tablets may be formulated to provide, on dissolution, a still
15 mouthwash, or, by the incorporation of a suitable effervescent couple, for instance sodium carbonate/bicarbonate and citric acid, an effervescent mouthwash.

The compositions of the present invention are of use in alleviating the symptoms of xerostomia. In particular they are of use in lubricating and hydrating the oral cavity.

20

The present invention also provides a method for treating xerostomia in a human or animal, wherein said method comprises administration of a therapeutically effective amount of a composition as hereinbefore described.

25

30

The present invention is illustrated by the following examples but is not limited thereby.

Example 1 – Mouthspray 1

Ingredient	Amount % w/w
Water	52.940
Glycerin	35.000
Xylitol	7.500
VP/VA copolymer	1.000
PEG 60 Hydrogenated castor oil	1.600
Flavour ingredients	0.810
Sodium benzoate	0.500
Xanthan gum	0.400
Methylparaben	0.100
Propylparaben	0.100
Cetylpyridinium chloride	0.050

5

Example 2 - Mouth spray 2

Ingredient	Amount % w/w
Water	51.750
Glycerin	35.000
Xylitol	7.500
PVP	2.640
PEG 60 Hydrogenated castor oil	0.850
Flavour ingredients	0.810
Sodium benzoate	0.500
Xanthan gum	0.400
Cellulose gum	0.400
Aloe Barbadensis	0.100
Cetylpyridinium chloride	0.050

Example 3 - Mouthwash

Ingredient	Amount % w/w
Water	84.214
Glycerin	7.000
Sorbitol	5.000
Poloxamer 338	1.000
PEG 60 Hydrogenated castor oil	1.000
VP/VA copolymer	0.750
Sodium benzoate	0.500
Cellulose gum	0.200
Flavour ingredients	0.120
Cetylpyridinium chloride	0.050
Methyl paraben	0.050
Propyl paraben	0.050
Sodium saccharin	0.050
Xanthan gum	0.010
Disodium phosphate	0.003
Sodium phosphate	0.002
FD&C Blue No. 1	0.001

Example 4 – Oral gel

Ingredient	Amount % w/w
PVP	8.000
Cellulose	1.000
Carbomer	1.000
Sorbitol	25.000
Xylitol	10.000
Glycerin	19.000
Flavour ingredients	0.100
FD&C Blue No. 1 (1% solution)	0.400
Water	35.500

Example 5 – Sensory Evaluation

Sensory evaluation for the optimisation of polymers for use in xerostomia applications was performed using small scale panel testing. Sensory findings include:

- 5 The use of CMC alone at a level which provides good mouth coating produced sensory negatives of 'tacky' and 'gloopy' .

Sensory testing of Xanthan gum alone, at levels which provided good mouth coating, produced negative sensory feedback of 'gloopy' and comments of tackiness

- 10 A blend of CMC, Xanthan gum and PVP was found to deliver good coating with a smooth, good mouthfeel and the ability to lubricate and hydrate the mouth. This polymer combination was tested alongside a CMC, Xanthan, Dimethicone combination. Substitution of the PVP for Dimethicone reduced the coating benefit and smoothness of the polymer blend.

- 15 The sensory negatives associated with the use of CMC or Xanthan alone, which deliver coating and mucoadhesion benefits, have been overcome by the incorporation of PVP in a combination of CMC and xanthan gum, this effect is further suggested by the loss of smoothness when PVP was substituted in the blend for an alternative polymer resulting in the loss of all smooth type comments.

Example 6 – Sensory evaluation

Further sensory evaluation for the optimisation of polymers for use in xerostomia applications was performed using small scale panel test consisting of six panelists.

5

Panelists tested 10ml of polymer solutions as shown in the table below:

Polymer Solution	CMC %w/w	Xanthan %w/w	PVP %w/w
Xanthan		1.0	
Xanthan+PVP		1.0	2.5
CMC	1.0		
CMC+PVP	1.0		2.5
Xanthan+CMC	0.75	0.25	
Xanthan+CMC+PVP	0.75	0.25	2.5

10 Sensory findings include:

CMC/CMC + PVP solutions

15 Addition of PVP to a CMC solution improved the organoleptic characteristics of the polymer solutions. PVP significantly ($p=0.01$) reduced the tackiness of the CMC solution and provided a smoother oral texture. The mouthfeel and aftertaste of the CMC + PVP solution was more pleasant. The mouth was more moisturised. Both polymer solutions were perceived to be moderately gloopy. There was a trend for the CMC + PVP solution to be perceived as being more viscous and gel like (more gloopy) than the CMC solution.

20 This is explained by the fact that there is more overall polymer increasing the viscosity of the solution.

Xanthan/Xanthan + PVP

25 In this small scale panel testing no significant difference was observed between the organoleptic characteristics of a xanthan solution and a mixture of xanthan and PVP. There was a trend that the addition of PVP to xanthan solution slightly reduced the pleasantness of the mouth feel and the smoothness of the oral texture of the solution

owing to an increased gloopy sensation, which can be explained by the increase in overall polymer in the system. However, adding PVP increased the ability to coat the mouth. Both polymers solutions were perceived leaving the mouth moderately moisturised and lubricated. Importantly the addition of PVP reduced the tackiness of the xanthan solution.

5

Xanthan + CMC/Xanthan + CMC + PVP

Addition of PVP to a xanthan + CMC solution improved significantly ($p=0.03$) the smoothness of the oral texture of the solution. There was a trend for PVP to reduce tackiness of the xanthan + CMC solution and to provide a more pleasant mouthfeel and to leave the mouth moisturised and lubricated. Xanthan + CMC + PVP solution was perceived to be more gloopy in view of the fact that there was more overall polymer increasing the viscosity of the solution.

10

CLAIMS

- 5 1. An oral care composition comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.
- 10 2. A composition according to claim 1, wherein the derivative of polyvinyl pyrrolidone is a vinylpyrrolidone/vinylacetate (VP/VA) copolymer or a vinylpyrrolidone/vinyl alcohol (VP/VOH) copolymer.
3. A composition according to claim 1 or 2 comprising PVP or VP/VA copolymer.
- 15 4. A composition according to any one of claims 1 to 3 in which the PVP or derivative thereof is present in the amount of 0.1 to 20% w/w.
- 20 5. A composition according to any one of claims 1 to 4 in which the anionic mucoadhesive polymer is selected from a cellulose gum, a saccharide gum or a polyacrylic acid polymer or a mixture thereof.
6. A composition according to claim 5, wherein the cellulose polymer is a carboxymethyl cellulose gum.
- 25 7. A composition according to claim 5 wherein the saccharide gum is selected from xanthan gum, guar gum, gum Arabic, tragacanth, gum karaya, locust bean gum and pectin or a mixture thereof.
- 30 8. A composition according to claim 7 wherein the saccharide is xanthan gum.
9. A composition according to claim 5 wherein the polyacrylic acid polymer is a carbomer, an acrylate/C₁₀₋₃₀ alkyl acrylate cross polymer or a polycarbophil.
- 35 10. A composition according to claim 5 wherein the mucoadhesive polymer is a combination of sodium carboxymethyl cellulose and xanthan gum.

11. A composition according to any one of claims 1 to 10 wherein the anionic mucoadhesive polymer is present in the range 0.02 to 20% w/w.
- 5 12. A composition according to any one of claims 1 to 11 wherein the ratio of PVP or a derivative thereof to the anionic mucoadhesive polymer is from 5:1 to 1:1.
13. A composition according to any one of claims 1 to 12 for use as a lubricant in the oral cavity.
- 10 14. A composition according to any one of claims 1 to 13 for use in hydration of the oral cavity.
- 15 15. A composition according to any one of claims 1 to 14 for treating the symptoms of xerostomia.
16. A method of treating the symptoms of xerostomia which comprises the administration of a therapeutically effective amount of a composition according to any one of claims 1 to 12.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/008327

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K8/73 A61K8/81 A61Q11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/59423 A (WATSON PHARMACEUTICALS, INC) 12 October 2000 (2000-10-12) claims 1,4,5; examples 1,3,5-7,11,13	1-5,9, 11-16
X	PATENT ABSTRACTS OF JAPAN vol. 010, no. 078 (C-335), 27 March 1986 (1986-03-27) & JP 60 215622 A (TOYO BOSEKI KK), 29 October 1985 (1985-10-29) abstract	1-5,9, 11-15
X	PATENT ABSTRACTS OF JAPAN vol. 015, no. 163 (C-0826), 24 April 1991 (1991-04-24) & JP 03 034928 A (TEIKOKU SEIYAKU KK), 14 February 1991 (1991-02-14) abstract	1-5,9, 11-15
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 October 2005

Date of mailing of the international search report

02/11/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Donovan-Beermann, T

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/008327

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 010, no. 166 (C-353), 13 June 1986 (1986-06-13) & JP 61 017510 A (TOYO BOSEKI KK), 25 January 1986 (1986-01-25) abstract	1-5, 9, 11-15
X	EP 1 334 710 A (LACLEDE, INC) 13 August 2003 (2003-08-13) paragraph '0023!; claims 1,8,16; example 5	1-5, 9, 13-15
X	EP 0 781 550 A (ADIR ET COMPAGNIE; LES LABORATOIRES SERVIER) 2 July 1997 (1997-07-02) page 2, line 24 - line 35; claims 1,3	1-8, 13-15
X	WO 97/00665 A (HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN; WUELKNITZ, PETER; PASTURA, AM) 9 January 1997 (1997-01-09) page 4, paragraph 3 - page 5, paragraph 2 page 7, paragraph 4; claims; examples	1-5, 7, 11-15
X	US 4 292 299 A (SUZUKI ET AL) 29 September 1981 (1981-09-29) table 1	1-6, 12-15
X	US 2004/062724 A1 (MORO DANIEL G ET AL) 1 April 2004 (2004-04-01) cited in the application claims; examples 1-4	1-5, 11-15
X	WO 03/015748 A (ACCESS PHARMACEUTICALS, INC; MORO, DANIEL, G; CALLAHAN, HOWARD; NOWOTN) 27 February 2003 (2003-02-27) cited in the application claims; examples 3,4,7,11	1-5, 11-15
A	GB 2 194 145 A (* CATCHGATE LIMITED) 2 March 1988 (1988-03-02) the whole document	1
A	WO 92/03124 A (ORAMED, INC) 5 March 1992 (1992-03-05) page 33, line 27 - page 34, line 21	1
A	US 5 541 165 A (TURGEON ET AL) 30 July 1996 (1996-07-30) column 4, line 3 - line 17; claims 1,4	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/008327

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0059423	A	12-10-2000	AU 764912 B2 AU 4178600 A CA 2333156 A1 EP 1089686 A1 US 6210699 B1 US 2001051186 A1	04-09-2003 23-10-2000 12-10-2000 11-04-2001 03-04-2001 13-12-2001
JP 60215622	A	29-10-1985	JP 1832298 C JP 5030808 B	29-03-1994 11-05-1993
JP 03034928	A	14-02-1991	NONE	
JP 61017510	A	25-01-1986	NONE	
EP 1334710	A	13-08-2003	CA 2406802 A1 JP 2003238327 A US 2003143214 A1	29-07-2003 27-08-2003 31-07-2003
EP 0781550	A	02-07-1997	AT 222098 T AU 725283 B2 AU 7549696 A CA 2193454 A1 CN 1159950 A DE 69622980 D1 DE 69622980 T2 DK 781550 T3 ES 2180722 T3 FR 2742989 A1 JP 9194395 A NO 965475 A NZ 314009 A PT 781550 T US 5900247 A ZA 9610864 A	15-08-2002 12-10-2000 03-07-1997 30-06-1997 24-09-1997 19-09-2002 10-04-2003 09-12-2002 16-02-2003 04-07-1997 29-07-1997 30-06-1997 26-02-1998 29-11-2002 04-05-1999 27-06-1997
WO 9700665	A	09-01-1997	DE 19522750 A1	02-01-1997
US 4292299	A	29-09-1981	DE 2967009 D1 EP 0020777 A1 HK 80684 A WO 8000916 A1 JP 1138989 C JP 55062012 A JP 57029448 B MY 47086 A SG 52884 G	28-06-1984 07-01-1981 02-11-1984 15-05-1980 11-03-1983 10-05-1980 23-06-1982 31-12-1986 08-03-1985
US 2004062724	A1	01-04-2004	CA 2459692 A1 EP 1418889 A2 HU 0401281 A2 JP 2005504763 T MX PA04001491 A WO 03015748 A2 US 2003044446 A1	27-02-2003 19-05-2004 29-11-2004 17-02-2005 17-05-2004 27-02-2003 06-03-2003
WO 03015748	A	27-02-2003	CA 2459692 A1 EP 1418889 A2 HU 0401281 A2	27-02-2003 19-05-2004 29-11-2004

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/008327

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03015748	A	JP 2005504763 T MX PA04001491 A US 2004062724 A1 US 2003044446 A1	17-02-2005 17-05-2004 01-04-2004 06-03-2003
GB 2194145	A	02-03-1988 IE 58858 B1 ZA 8701132 A	17-11-1993 11-08-1987
WO 9203124	A	05-03-1992 AT 137404 T AU 8444291 A DE 69119217 D1 DE 69119217 T2 DK 497956 T3 EP 0497956 A1 ES 2088500 T3 GR 3020502 T3 JP 5502894 T JP 3064417 B2	15-05-1996 17-03-1992 05-06-1996 31-10-1996 12-08-1996 12-08-1992 16-08-1996 31-10-1996 20-05-1993 12-07-2000
US 5541165	A	30-07-1996 NONE	